一心堂(002727) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥3,796,735,445.93, an increase of 18.29% compared to the same period last year[3] - Net profit attributable to shareholders was ¥240,034,304.78, reflecting a growth of 27.83% year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥235,900,947.79, up by 31.07% compared to the previous year[3] - The basic earnings per share (EPS) was ¥0.4067, representing a 22.94% increase year-on-year[3] - Total operating revenue for the third quarter of 2021 reached ¥10,498,301,379.32, an increase of 13.7% compared to ¥9,238,762,435.38 in the same period of 2020[32] - Net profit for the third quarter was ¥762,213,079.85, representing a 26.2% increase from ¥603,994,637.57 in the previous year[35] - The company reported a profit before tax of ¥870,155,127.54, compared to ¥767,510,240.34 in the previous year, an increase of 13.4%[35] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥13,447,513,540.76, a 44.16% increase from the end of the previous year[3] - The company's total liabilities increased to ¥6,940,241,350.55 from ¥3,547,811,380.18, marking an increase of 95.5% year-over-year[28] - The total equity attributable to shareholders of the parent company rose to ¥6,406,303,508.53, up from ¥5,765,406,145.25, indicating an increase of 11.1%[28] - Total assets reached ¥13,447,513,540.76 as of September 30, 2021, compared to ¥9,328,305,421.12 at the end of 2020, showing an increase of approximately 44.5%[25] - Total liabilities increased from 3.55 billion to 5.49 billion, reflecting a growth of about 54.7%[50] - Current liabilities increased from 3.53 billion to 4.23 billion, an increase of approximately 19.6%[50] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥759,819,437.97, showing a growth of 12.90%[3] - The company reported a 394.30% increase in net cash flow from investing activities to CNY 673,651,861.65, due to the recovery of maturing financial products[10] - Operating cash inflow from sales reached ¥10,035,983,929.82, up from ¥9,090,618,492.56, indicating an increase of about 10.4%[38] - Net cash flow from operating activities was ¥759,819,437.97, compared to ¥673,004,795.75 in the previous period, reflecting a growth of approximately 12.9%[38] - Total cash and cash equivalents at the end of the period stood at ¥1,541,494,011.21, an increase from ¥1,431,295,226.83, representing a growth of about 7.7%[41] Investments and Expenses - Research and development expenses surged by 343.49% to CNY 3,866,498.12, reflecting increased investment in traditional Chinese medicine projects[9] - Financial expenses skyrocketed by 1422.04% to CNY 56,993,715.76, mainly due to increased leasing interest expenses following the new leasing standards[9] - Research and development expenses for the quarter were ¥3,866,498.12, significantly higher than ¥871,840.16 in the same period last year, reflecting a focus on innovation[32] - The company’s cash flow from investment activities was significantly impacted, with cash paid for investments totaling ¥1,472,800,741.00, down from ¥3,731,200,000.00, a decrease of about 60.5%[41] Market Expansion and Strategy - The company did not report any significant new product developments or market expansion strategies during this quarter[8] - The company continues to expand its market presence, focusing on the Sichuan-Chongqing region and enhancing its network layout[18] - The company aims to enhance its brand influence and sales capabilities through a structured approach to market expansion[21] - The company is actively exploring digital development paths and innovative business models to meet diverse consumer health service needs[18] Store Operations - As of September 30, 2021, the total number of direct chain stores reached 8,356, with a net increase of 1,151 stores during the reporting period[18] - The company opened 1,300 new stores while closing 26 and relocating 123 stores in the same period[21] Other Financial Metrics - The weighted average return on equity (ROE) was 3.73%, a slight increase of 0.02% compared to the previous year[3] - Minority interests surged by 569.20% to CNY 100,968,681.68, resulting from the acquisition of Bencao Tang[9] - Deferred tax assets remained unchanged at 27.62 million, indicating stability in this area[50] - The company reported a total of 2.61 billion in non-current assets as of December 31, 2020, which increased to 4.88 billion by January 1, 2021[50] Audit and Reporting - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[51]